Only one of the 47 cases that recurred expressed no COX-2 (2%) and only five (11%) expressed weak COX-2 (Table 1), compared to 16% (18/114) and 18% (21/114) cases of nonrecurrent DCIS expressing none or weak staining, respectively. This evidence concerns the gene PTGS2 and ductal breast carcinoma in situ.